A Comparative Study on Atorvastatin Versus Methotrexate in Rheumatoid Arthritis in a Double Blind Placebo Control Trial.


M Sandooghi 1 , Z Zakeri 2 , * , S Almasy 3 , AR Dashipour 4

1 Assistant Professor,

2 Associate Professor, Section of Rheumatology, Department of In-ternal Medicine, Ali-Ebn-Abitaleb Hospital, Zahedan University of Medical Sciences, Za-hedan, Iran,

3 Assistant Professor, Section of Rheumatology, Department of Internal Medicine, Firoozgar Hospital, Tehran University of Medical Sciences, Tehran, Iran,

4 MSc in Nutrition , Zahedan University of Medical Sciences, Zahedan, Iran.

How to Cite: Sandooghi M, Zakeri Z, Almasy S, Dashipour A. A Comparative Study on Atorvastatin Versus Methotrexate in Rheumatoid Arthritis in a Double Blind Placebo Control Trial., Shiraz E-Med J. Online ahead of Print ; 12(4):189-95.


Shiraz E-Medical Journal: 12 (4); 189-95
Published Online: October 1, 2011
Article Type: Research Article
Received: September 26, 2010
Accepted: October 1, 2011


Background: The therapeutic effects of methotrexate (MTX) are well-known in rheumatoid arthritis(RA).Also,anti inflammatory effects of atorvastatin have already been reported, but no study has compared the effects of these two drugs on RA.Therefore we designed this study to compare the effects of these drugs on patients with active RA.

Method: The study was conducted on 54 patients with active RA who had been undergoing Disease Modifying -Anti Rheumatic- Drugs therapy for at least 3 months that included 7.5 mg methotrexate weekly. They were allocated into two groups. In addition to the 7.5 mg of MTX, one group received another 7.5 mg of MTX weekly and placebo daily and the other group received atorvastatin 40 mg daily and placebo weekly. They were followed up for 12 weeks. Some clinical aspects and the disease activity score (DAS) were evaluated at the beginning of the study and then at the weeks of 6th and 12th.

Results: After multiple comparisons by repeated measures, disease activity score and other variables showed a significant reduction in both groups at 12th week after treatment; however, the effect of both interventions was similar in change of DAS and other variables except for duration of morning stiffness, that it decreased more in statin than MTX group. No significant side effects causing to exclude the patients from the study were observed in any of the two groups.

Conclusion: we concluded that statin, can serve an important role in treatment of RA.

Full Text

Full text is available in PDF

© 2011, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.